Atrys Health S.A (ATRY) | Stock Overview & Key Data
Atrys Health S.A. | Mid-cap | Healthcare
Atrys Health S.A. | Mid-cap | Healthcare
Atrys Health S.A Performance Comparison
Stock Range
Today's Range
Low: €2.80
High: €2.85
on August 8, 2025
52 Week Range
Low: €2.48
High: €3.79
on June 24, 2025
on October 14, 2024
All-Time High: €11.25 on August 30, 2021
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€214.1M
EPS
-0.42
P/E Ratio (TTM)
-6.69
Forward P/E
35.13
P/B Ratio
0.85
PEG Ratio
0.22
Div. Yield
N/A
ROE
-11.73%
Beta
0.669
Debt to Equity
100.85
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
3.20%
Profit Margin
-14.57%
Returns and Earnings
Return on Assets (TTM)
0.20%
Return on Equity (TTM)
-11.73%
EBITDA
€36.0M
Net Income (TTM)
€-31.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€2.87
Quarterly Revenue Growth (YoY)
6.90%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Atrys Health S.A ATRY | 214.06M Mid-cap | -4.11% | 8.95% | -5.08% | -21.79% | -20.00% | -7.89% | -54.55% | -62.57% |
| Pharma Mar S.A PHM | 1.41B Large-cap | -1.68% | -5.57% | 7.28% | -13.02% | -1.50% | 116.43% | 25.69% | -6.61% |
| Oryzon Genomics S.A ORY | 203.86M Mid-cap | -2.65% | -4.46% | -3.38% | 72.48% | 71.33% | 48.57% | 1.17% | -4.41% |
| Vytrus Biotech S.A VYT | 41.38M Small-cap | -9.09% | 22.22% | 70.81% | 133.05% | 154.63% | 71.34% | 77.42% | 95.04% |
| Biotechnology Assets BST | 24.09M Small-cap | 0.00% | -12.20% | 24.14% | 0.00% | 28.57% | 16.13% | 89.47% | -53.85% |
| Grifols, S.A GRF | 7.93B Large-cap | -2.06% | 22.50% | 57.28% | 54.08% | 35.84% | 46.52% | -6.61% | -47.55% |
Ownership & Short Interest
Insider Ownership
54.56%
Institutional Ownership
10.04%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
26K
Average 90-Day Volume
54K
Atrys Health S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Atrys Health S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ATRY's 52-week high and low?
- In the last 52 weeks, Atrys Health S.A reached a high of €3.79 (on October 14, 2024) and a low of €2.48 (on June 24, 2025).
- What is the market cap and P/E ratio for ATRY?
- Curious about Atrys Health S.A's size and valuation? Its market capitalization stands at 214.06M. When it comes to valuation, the P/E ratio (trailing twelve months) is -6.69, and the forward P/E (looking ahead) is 35.13.
- Does ATRY pay dividends? If so, what's the yield?
- As for dividends, Atrys Health S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Atrys Health S.A's main competitors or similar companies to consider before investing?
When looking at Atrys Health S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pharma Mar S.A
PHM1.41B Healthcare Biotechnology 116.43% 25.69% Oryzon Genomics S.A
ORY203.86M Healthcare Biotechnology 48.57% 1.17% Vytrus Biotech S.A
VYT41.38M Healthcare Biotechnology 71.34% 77.42% Biotechnology Assets
BST24.09M Healthcare Biotechnology 16.13% 89.47% Grifols, S.A
GRF7.93B Healthcare Drug Manufacturers - General 46.52% -6.61% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Atrys Health S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Atrys Health S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -11.73%, the Debt to Equity ratio from the most recent quarter is 100.85, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ATRY?
- Looking at Atrys Health S.A's growth, its revenue over the trailing twelve months (TTM) was €218M. Compared to the same quarter last year (YoY), quarterly revenue grew by 6.90%, and quarterly earnings saw a YoY growth of N/A.
- How much of ATRY stock is held by insiders and institutions?
- Wondering who owns Atrys Health S.A stock? Company insiders (like executives and directors) hold about 54.56% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 10.04%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.